Compare Otis Worldwide Corp (OTIS) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Tempus AI — how do they compare? Otis Worldwide Corp trades at $66.12 (market cap $25.17B), while Tempus AI trades at $70.03 (market cap $12.58B). The key difference: Otis Worldwide Corp is far larger — about 2× Tempus AI's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 65 Days and Tempus AI for 22 Days on average.
| OTIS | TEM | |
|---|---|---|
Market Cap | $25.17B | $12.58B |
Volume | 4,542,442 | 7,444,569 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $93.62 | $99.28 |
52-Week Low | $64.05 | $41.55 |
Typical Hold Time | 65 Days | 22 Days |
Enterprise Value | $33.20B | $13.21B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $65.74, down 1.07% on the day and near its 52-week low, reflecting bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B USD with a net income margin of 10.17%, but faces margin pressure and a high debt-to-asset ratio of 75.54%. Recent news highlights CEO succession plans and mixed sentiment amid weak equipment demand in China.
The outlook is cautious with moderate upside to the $87.00 consensus price target, supported by a dominant service segment and institutional accumulation. Key risks include persistent margin compression, China exposure, and elevated leverage, requiring monitoring of service margin recovery for sustained growth.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.
The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
